217 related articles for article (PubMed ID: 32826324)
1. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors of Renal Recovery and Progression to End-Stage Kidney Disease in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis With Severe Kidney Disease.
Casal Moura M; Zubidat D; Liebana MP; Sethi S; Soler MJ; Zand L; Dos Santos FG; Nardelli L; Leon-Roman J; Sousa C; Warrington KJ; Specks U; Fervenza FC
Kidney Int Rep; 2024 May; 9(5):1284-1297. PubMed ID: 38707835
[TBL] [Abstract][Full Text] [Related]
3. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Iklé D; Villarreal M; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheumatol; 2014 Nov; 66(11):3151-9. PubMed ID: 25047592
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of protein A immunoadsorption therapy on severe ANCA-associated vasculitis renal injury.
Song J; Liu H; Chen X; Zhou L; Sun C; Yuan F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1026-1032. PubMed ID: 37724405
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
[TBL] [Abstract][Full Text] [Related]
7. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM; Jones RB; Specks U; Bond S; Nodale M; Al-Jayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Ferraro A; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani R; McAlear C; Moreland LW; Mynard K; Nachman P; Pagnoux C; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Wroe C; Jayne D; Merkel PA;
Ann Rheum Dis; 2023 Jul; 82(7):937-944. PubMed ID: 36958796
[TBL] [Abstract][Full Text] [Related]
8. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
Gamerith G; Mildner F; Merkel PA; Harris K; Cooney L; Lim N; Spiera R; Seo P; Langford CA; Hoffman GS; St Clair EW; Fervenza FC; Monach P; Ytterberg SR; Geetha D; Amann A; Wolf D; Specks U; Stone JH; Kronbichler A
Ann Rheum Dis; 2023 Feb; 82(2):253-261. PubMed ID: 35973802
[TBL] [Abstract][Full Text] [Related]
9. Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Hillion S; Konig MF; Moura MC; Hummel AM; Carmona E; Peikert T; Fervenza FC; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; Brunetta P; St Clair EW; Harris KM; Stone JH; Grandi G; Pers JO; Specks U; Cornec D
Arthritis Rheumatol; 2023 May; 75(5):736-747. PubMed ID: 36281741
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide induction dose and outcomes in ANCA-associated vasculitis with renal involvement: A comparative cohort study.
Speer C; Altenmüller-Walther C; Splitthoff J; Nusshag C; Kälble F; Reichel P; Morath C; Zeier M; Bergner R; Schaier M
Medicine (Baltimore); 2021 Jul; 100(29):e26733. PubMed ID: 34398050
[TBL] [Abstract][Full Text] [Related]
11. Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS).
Fussner LA; Flores-Suárez LF; Cartin-Ceba R; Specks U; Cox PG; Jayne DRW; Merkel PA; Walsh M;
Am J Respir Crit Care Med; 2024 May; 209(9):1141-1151. PubMed ID: 38346237
[No Abstract] [Full Text] [Related]
12. Sustained post-rituximab B-cell depletion is common in ANCA-associated vasculitis and is affected by sex and renal function.
Mescia F; Salviani C; Tonoli M; Affatato S; Moratto D; Tedesco M; Guerini A; Gemmo A; Camoni M; Delbarba E; Zubani R; Garrafa E; Chiarini M; Gregorini G; Scolari F; Alberici F
Nephrol Dial Transplant; 2024 Mar; 39(4):683-693. PubMed ID: 37673675
[TBL] [Abstract][Full Text] [Related]
13. Relevance of histopathological findings for predictive scoring of short-term treatment response to plasma exchange in severe ANCA-associated renal vasculitides.
Hakroush S; Korsten P; Ströbel P; Tampe B
Front Immunol; 2024; 15():1340999. PubMed ID: 38380320
[TBL] [Abstract][Full Text] [Related]
14. Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.
Salvadori M; Tsalouchos A
World J Nephrol; 2018 May; 7(3):71-83. PubMed ID: 29736379
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
Cornec D; Kabat BF; Mills JR; Cheu M; Hummel AM; Schroeder DR; Cascino MD; Brunetta P; Murray DL; Snyder MR; Fervenza F; Hoffman GS; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Barnidge DR; Specks U
Rheumatology (Oxford); 2018 Apr; 57(4):639-650. PubMed ID: 29340623
[TBL] [Abstract][Full Text] [Related]
16. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
McClure ME; Zhu Y; Smith RM; Gopaluni S; Tieu J; Pope T; Kristensen KE; Jayne DRW; Barrett J; Jones RB
Rheumatology (Oxford); 2021 Mar; 60(3):1491-1501. PubMed ID: 33141217
[TBL] [Abstract][Full Text] [Related]
17. Impact of concurrent glomerulonephritis on outcomes of diffuse alveolar haemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis.
Cohen SP; Wodarcyk AJ; Wong A; Patterson KC; Lyons MI; Barnes A; Strickland A; Pan X; Almaani S; Meara AS; Crouser ED; Wewers MD; Fussner LA
Clin Exp Rheumatol; 2024 Apr; 42(4):811-815. PubMed ID: 37976113
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: A cohort study.
Liberatore J; Nguyen Y; Hadjadj J; Cohen P; Mouthon L; Puéchal X; Guillevin L; Terrier B
J Autoimmun; 2024 Jan; 142():103130. PubMed ID: 37956529
[TBL] [Abstract][Full Text] [Related]
19. The Challenge of Assessing Remission and Relapse in ANCA Kidney Disease.
Brix SR
J Am Soc Nephrol; 2024 Apr; 35(4):395-397. PubMed ID: 38557787
[No Abstract] [Full Text] [Related]
20. Relapse in patients with antineutrophil cytoplasmic antibody-associated vasculitis undergoing dialysis: a single-centre retrospective study in South Korea.
Lee YJ; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
Clin Exp Rheumatol; 2024 Apr; 42(4):828-833. PubMed ID: 38153168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
